NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BIOFILCHEM · data 2026-10-30
Biofil Chemicals & Pharmaceuticals Ltd.
In plain words
Price: 38.1% below its 52-week high of ₹46.34.
Delivery: 63.8% of traded shares were kept for delivery over the last 10 sessions, against 69.5% over the last 60.
Latest results: a net profit of ₹0 cr for the quarter ended Jun 2026 (-95.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹34 cr |
| Net profit (last 12 months) | ₹0 cr |
| Sales growth, 3 years (yearly) | -1.9% |
| Profit growth, 3 years (yearly) | 70.7% |
Latest results in brief (Q1 FY27)
BIOFILCHEM Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹12.35 crore, up 92.1% YoY and up 63.1% QoQ.
Net profit was ₹0.11 crore, down 95.4% YoY and down 47.6% QoQ.
Operating margin was 1.1% (0.1% a year ago).
EPS was ₹0.07, down 95.3% YoY and down 46.2% QoQ.
BIOFILCHEM के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹12.35 करोड़; पिछले साल की तुलना में 92.1% की बढ़त, पिछली तिमाही की तुलना में 63.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹0.11 करोड़; पिछले साल की तुलना में 95.4% की गिरावट, पिछली तिमाही की तुलना में 47.6% की गिरावट।
ऑपरेटिंग मार्जिन: 1.1% (एक साल पहले 0.1%)।
EPS: ₹0.07; पिछले साल की तुलना में 95.3% की गिरावट, पिछली तिमाही की तुलना में 46.2% की गिरावट।
BIOFILCHEMના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹12.35 કરોડ; ગયા વર્ષની સરખામણીએ 92.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 63.1% વધારો.
ચોખ્ખો નફો: ₹0.11 કરોડ; ગયા વર્ષની સરખામણીએ 95.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 47.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 1.1% (એક વર્ષ પહેલાં 0.1%).
EPS: ₹0.07; ગયા વર્ષની સરખામણીએ 95.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 46.2% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 61.9% over the last 20 sessions vs 52.5% in the 40 before (1.18x); shares delivered per day 0.14x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 11 Aug 26Results Q1 FY27 results: profit −95.4% YoY +0.1% next session
- 30 May 26Results Q4 FY26 results: profit +5.0% YoY -0.8% next session
- 13 Feb 26Results Q3 FY26 results: profit −50.0% YoY -7.0% next session
- 13 Nov 25Results Q2 FY26 results: profit +300.0% YoY -1.9% next session
- 12 Aug 25Results Q1 FY26 results: profit +1317.6% YoY -1.6% next session
- 30 May 25Results Q4 FY25 results: profit −20.0% YoY -4.6% next session
- 11 Feb 25Results Q3 FY25 results: profit +77.8% YoY -2.7% next session
- 15 Nov 24Results Q2 FY25 results: profit −83.3% YoY -3.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹12 cr | ₹0 cr | -95.4% | 1.1% | 0.07 |
| Mar 2026 | ₹8 cr | ₹0 cr | +5.0% | 5.7% | 0.13 |
| Dec 2025 | ₹1 cr | ₹0 cr | -50.0% | 11.1% | 0.05 |
| Sept 2025 | ₹14 cr | ₹0 cr | +300.0% | 0.8% | 0.05 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 46.79% | 46.79% | 46.79% | 46.79% |
| Foreign institutions (FII) | — | — | — | — |
| Domestic institutions (DII) | 0.08% | 0.08% | 0.08% | 0.08% |
| Mutual funds | — | — | — | — |
| Retail investors | 34.74% | 34.97% | 34.87% | 34.67% |
| Number of shareholders | 24,660 | 24,999 | 25,356 | 24,825 |
Common questions
What was Biofil Chemicals & Pharmaceuticals Ltd.'s latest quarterly profit?
Biofil Chemicals & Pharmaceuticals Ltd. reported a net profit of ₹0 cr for the quarter ended Jun 2026 (-95.4% on the same quarter a year earlier), on revenue of ₹12 cr.
How much do promoters hold in Biofil Chemicals & Pharmaceuticals Ltd.?
Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Biofil Chemicals & Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.14.
What is Biofil Chemicals & Pharmaceuticals Ltd.'s P/E ratio?
About 96.4, based on the last 12 months' earnings and a price of ₹28.68 (data 2026-10-30).
What is the 52-week high and low of Biofil Chemicals & Pharmaceuticals Ltd.?
The 52-week high is ₹46.34 and the 52-week low is ₹25.6.
Similar companies
Onyx Biotec Ltd. (ONYX) · Zenith Drugs Ltd. (ZENITHDRUG) · Vivimed Labs Limited (VIVIMEDLAB) · Mangalam Drugs & Organics Ltd. (MANGALAM) · Medicamen Organics Ltd. (MEDIORG)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BIOFILCHEM in NSE Scanner →